Molecular Partners AG ADR
$ 5.05
0.60%
25 Feb - close price
- Market Cap 187,744,000 USD
- Current Price $ 5.05
- High / Low $ 5.11 / 5.05
- Stock P/E N/A
- Book Value 3.30
- EPS -2.09
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.51 %
- 52 Week High 5.11
- 52 Week Low 3.36
About
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company is headquartered in Schlieren, Switzerland.
Analyst Target Price
$12.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-25 | 2025-04-17 | 2025-03-06 | 2024-10-31 | 2024-08-27 | 2024-05-16 | 2024-03-14 | 2023-10-26 | 2023-08-28 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.4021 | -0.6867 | -0.45 | -0.3 | -0.5629 | -0.46 | -0.6 | -0.6 | -0.3943 | -0.5417 | -0.4906 | -0.54 |
| Estimated EPS | -0.4795 | -0.4995 | -0.37 | -0.39 | -0.6288 | -1.26 | -1 | -0.97 | 0 | -0.87 | 0 | -0.9 |
| Surprise | 0.0774 | -0.1872 | -0.08 | 0.09 | 0.0659 | 0.8 | 0.4 | 0.37 | -0.3943 | 0.3283 | -0.4906 | 0.36 |
| Surprise Percentage | 16.1418% | -37.4775% | -21.6216% | 23.0769% | 10.4803% | 63.4921% | 40% | 38.1443% | None% | 37.7356% | None% | 40% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.38 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MOLN
2026-02-23 06:03:09
Molecular Partners AG (MOLN.SW) is down 6.09% pre-market on February 23, 2026, trading at CHF 3.94, driven by investor caution ahead of upcoming clinical readouts and the 2026 earnings announcement on March 12, 2026. Despite negative earnings per share, the clinical-stage biotech maintains a healthy current ratio. Meyka AI forecasts a potential downside, while analysts consider bear, base, and bull case price targets influenced by clinical progress and licensing deals.
2026-02-20 03:27:23
Molecular Partners (MOLN.SW) saw an 8.84% pre-market gain, trading at CHF 3.94 with high volume, driven by technical factors and anticipation of March earnings and clinical catalysts. Despite positive technical indicators and a solid cash position, Meyka AI rates the stock as "HOLD" due to negative EPS and operating cash flow, projecting a potential 33.67% downside over 12 months. Investors are advised to monitor upcoming trial readouts and partnership news closely.
2026-02-17 11:27:26
Molecular Partners AG (MOLN.SW) saw a 6.16% pre-market jump on February 17, 2026, driven by increased trade interest, positive sector momentum, and anticipation of upcoming clinical readouts and March earnings. The company maintains typical clinical-stage biotech fundamentals with negative EPS but strong liquidity. Meyka AI gives MOLN.SW a "HOLD" rating with a conservative price target of CHF 3.80, while technical indicators suggest short-term momentum.
2026-02-03 04:59:04
Molecular Partners (NASDAQ: MOLN) presented promising imaging and dosimetry data for its DLL3-targeting radiotherapeutic program, MP0712, with a U.S. Phase I/II trial now open for screening. Data from compassionate-use patients showed favorable biodistribution, with tumor uptake and retention and low healthy-organ background, supporting projected therapeutic use of Lead-212. The company anticipates safety updates in H1 and early activity readouts in H2 2026, with potential for repeat dosing and future exploration of Actinium-225.
2026-02-02 20:27:44
Molecular Partners announced favorable imaging and dosimetry data for its DLL3-targeting radiotherapeutic program, MP0712, based on compassionate-use patients. The data showed promising biodistribution with tumor uptake and retention, and low healthy-organ background, supporting potential repeat dosing. The U.S. Phase I/II trial is expected to begin screening patients soon, with initial safety updates planned for H1 2026 and early activity readouts in H2 2026.
2026-02-02 17:28:12
Molecular Partners announced positive first imaging and dosimetry data for its DLL3-targeting Radio-DARPin candidate, MP0712, presented at the 8th Theranostics World Congress. The data, generated from five patients receiving diagnostic isotope 203Pb-labeled MP0712, showed promising tumor uptake with limited healthy tissue accumulation, highly supporting its clinical development for small cell lung cancer and other DLL3-expressing neuroendocrine cancers. A Phase 1/2a study of MP0712 with the therapeutic isotope 212Pb is currently recruiting in the U.S., with initial clinical data anticipated in 2026.
